Jenny Zilberberg

Jenny Zilberberg

Company: Imvax Inc.

Job title: Head of Research


The GoldspireTM Platform: A Personalized Biologic-Device Combination Approach to Generate Innate & Adaptive Anti-Tumor Immunity via Immunogenic Cell Death Mechanisms 3:30 pm

Positive results seen in Phase 1b GBM trial Phase 2b study is recruiting Immunogenic cell death-associated markers in combination with evidence of anti-tumor immune responses in murine models and patient samples supports the underlying mechanism of action of GoldspireTMRead more

day: Conference Day Two

A Hanson Wade Group Company

© Copyright 2024 Hanson Wade | Design and site by Event Engine | Hanson Wade Limited is registered in England & Wales, number 06752216.
Registered Office: Eastcastle House, 27/28 Eastcastle Street, London, W1W 8DH.